Transforming Hospitalizations of Autistic Adolescents via a Novel ABA Telehealth Platform

You said: Phase II TABA Research Strategy 1R44MH134706.pdf PDF based on the attached plan, what is a good 'Project Summary/Abstract' in the convenƟonal terminology and length typically done for a Phase II AdministraƟve Supplement for TABA? ChatGPT said: ChatGPT Here’s a convenƟonal "Project Summary/Abstract" based on the attached Phase II TABA plan: Project Summary/Abstract We are requesƟng Phase II Technical and Business Assistance (TABA) funding to advance the commercializaƟon of Hospital TeleABA, an innovaƟve telehealth platiorm designed to support hospital care for auƟsƟc children and adolescents. This funding will enable the strategic implementaƟon of our soluƟon into hospital systems, with plans for future expansion into schools and residenƟal settings for auƟsƟc teens and adults. Our Phase I research demonstrated the feasibility and potenƟal of Hospital TeleABA to enhance behavioral support for hospitalized adolescents with auƟsm. Over 109 I-Corps interviews and more than 120 stakeholder feedback sessions validated the need for our telehealth soluƟon, confirming its uƟlity in improving behavior management and discharge planning. The prototype we developed successfully integrated trauma-informed behavior stabilizaƟon (TIBS) protocols, and preliminary trials demonstrated strong clinical uƟlity, with a 97% correlaƟon in behavior idenƟficaƟon between remote observers and in- person evaluaƟons. To ensure successful commercializaƟon, we will leverage TABA funding to access strategic guidance in markeƟng, regulatory compliance, and reimbursement pracƟces. This will be facilitated through partnerships with the Council of AuƟsm Service Providers (CASP) and DRA CollecƟve, Inc., who will provide criƟcal experƟse in operaƟonal guidelines, billing pracƟces, and strategic market posiƟoning. Our goal is to establish Hospital TeleABA as the leading telehealth platiorm for behavioral support in hospital settings, while building the capacity to scale naƟonwide. With TABA support, we aim to solidify our market presence ahead of clinical trials set to begin in early 2025, ensuring that our soluƟon meets the high standards of care expected in hospitals, while also aligning with the best pracƟces established by CASP.